NM_057176.3:c.859G>T
Variant summary
Our verdict is Likely pathogenic. The variant received 6 ACMG points: 6P and 0B. PVS1_StrongPM2
The NM_057176.3(BSND):c.859G>T(p.Glu287*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000178 in 1,461,872 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Synonymous variant affecting the same amino acid position (i.e. E287E) has been classified as Likely benign.
Frequency
Consequence
NM_057176.3 stop_gained
Scores
Clinical Significance
Conservation
Publications
- Bartter disease type 4AInheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, G2P, PanelApp Australia
- Bartter syndrome type 4Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- hearing loss, autosomal recessiveInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Likely_pathogenic. The variant received 6 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes  
GnomAD2 exomes  AF:  0.00000398  AC: 1AN: 251428 AF XY:  0.00000736   show subpopulations 
GnomAD4 exome  AF:  0.0000178  AC: 26AN: 1461872Hom.:  0  Cov.: 31 AF XY:  0.0000151  AC XY: 11AN XY: 727228 show subpopulations 
Age Distribution
GnomAD4 genome  
ClinVar
Submissions by phenotype
not specified    Uncertain:1 
The p.Glu287X variant in BSND has not been previously reported in individuals wi th hearing loss or Bartter syndrome, but has been identified in 1/66718 European chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitu te.org; dbSNP rs376784896). Although this variant has been seen in the general p opulation, its frequency is not high enough to rule out a pathogenic role. This nonsense variant leads to a premature termination codon at position 287. This al teration occurs within the last exon and is likely to escape nonsense mediated d ecay (NMD) and to result in a truncated product 10% shorter than the normal prot ein. It is unclear whether the truncation impacts the protein function. In summa ry, the clinical significance of the p.Glu287X variant is uncertain. -
Inborn genetic diseases    Uncertain:1 
The c.859G>T (p.E287*) alteration, located in exon 4 (coding exon 4) of the BSND gene, consists of a G to T substitution at nucleotide position 859. This changes the amino acid from a glutamic acid (E) to a stop codon at amino acid position 287. Premature stop codons are typically deleterious in nature (Richards, 2015). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
Bartter disease type 4A    Uncertain:1 
ACMG: PM2, PM4 -
not provided    Uncertain:1 
This sequence change creates a premature translational stop signal (p.Glu287*) in the BSND gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 34 amino acid(s) of the BSND protein. This variant is present in population databases (rs376784896, gnomAD 0.0009%). This variant has not been reported in the literature in individuals affected with BSND-related conditions. ClinVar contains an entry for this variant (Variation ID: 505171). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Bartter syndrome    Uncertain:1 
- -
Computational scores
Source: 
Splicing
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at